Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2016

Open Access 01-12-2016 | Original investigation

Clinical outcomes of deferred revascularisation using fractional flow reserve in patients with and without diabetes mellitus

Authors: Mark W. Kennedy, Eliza Kaplan, Rik S. Hermanides, Enrico Fabris, Veemal Hemradj, Petra C. Koopmans, Jan-Hank E. Dambrink, A. T. Marcel Gosselink, Arnoud W. J. van‘t Hof, Jan Paul Ottervanger, Vincent Roolvink, Wouter S. Remkes, Aize van der Sluis, Harry Suryapranata, Elvin Kedhi

Published in: Cardiovascular Diabetology | Issue 1/2016

Login to get access

Abstract

Objective

Deferred revascularisation based upon fractional flow reserve (FFR >0.80) is associated with a low incidence of target lesion failure (TLF). Whether deferred revascularisation is also as safe in diabetes mellitus (DM) patients is unknown.

Methods

All DM patients and the next consecutive Non-DM patients who underwent a FFR-assessment between 1/01/2010 and 31/12/2013 were included, and followed until 1/07/2015. Patients with lesions FFR >0.80 were analysed according to the presence vs. absence of DM, while patients who underwent index revascularisation in FFR-assessed or other lesions were excluded. The primary endpoint was the incidence of TLF; a composite of target lesion revascularisation (TLR) and target vessel myocardial infarction (TVMI).

Results

A total of 250 patients (122 DM, 128 non-DM) who underwent deferred revascularisation of all lesions (FFR >0.80) were compared. At a mean follow up of 39.8 ± 16.3 months, DM patients compared to non-DM had a higher TLF rate, 18.1 vs 7.5 %, logrank p ≤ 0.01, Cox regression-adjusted HR 3.65 (95 % CI 1.40–9.53, p < 0.01), which was largely driven by a higher incidence of TLR (17.2 vs. 7.5 %, HR 3.52, 95 % CI 1.34–9.30, p = 0.01), whilst a non-significant but numerically higher incidence of TVMI (6.1 vs. 2.0 %, HR 3.34, 95 % CI 0.64–17.30, p = 0.15) was observed.

Conclusions

This study, the largest to directly compare the clinical outcomes of FFR-guided deferred revascularisation in patients with and without DM, shows that DM patients are associated with a significantly higher TLF rate. Whether intravascular imaging, additional invasive haemodynamics or stringent risk factor modification may impact on this higher TLF rate remains unknown.
Literature
1.
go back to reference Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van’t Veer M, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009;360(3):213–24.CrossRefPubMed Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van’t Veer M, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009;360(3):213–24.CrossRefPubMed
2.
go back to reference Fearon WF, Bornschein B, Tonino PA, Gothe RM, Bruyne BD, Pijls NH, et al. Economic evaluation of fractional flow reserve-guided percutaneous coronary intervention in patients with multivessel disease. Circulation. 2010;122(24):2545–50.CrossRefPubMed Fearon WF, Bornschein B, Tonino PA, Gothe RM, Bruyne BD, Pijls NH, et al. Economic evaluation of fractional flow reserve-guided percutaneous coronary intervention in patients with multivessel disease. Circulation. 2010;122(24):2545–50.CrossRefPubMed
3.
go back to reference Pijls NH, van Schaardenburgh P, Manoharan G, Boersma E, Bech JW, van’t Veer M, et al. Percutaneous coronary intervention of functionally nonsignificant stenosis 5-year follow-up of the DEFER Study. J Am Coll Cardiol. 2007;49(21):2105–11.CrossRefPubMed Pijls NH, van Schaardenburgh P, Manoharan G, Boersma E, Bech JW, van’t Veer M, et al. Percutaneous coronary intervention of functionally nonsignificant stenosis 5-year follow-up of the DEFER Study. J Am Coll Cardiol. 2007;49(21):2105–11.CrossRefPubMed
4.
go back to reference Jimenez-Quevedo P, Sabate M, Angiolillo D, Alfonso F, Hernandez-Antolin R, Banuelos C, et al. LDL-cholesterol predicts negative coronary artery remodelling in diabetic patients: an intravascular ultrasound study. Eur Heart J. 2005;26(21):2307–12.CrossRefPubMed Jimenez-Quevedo P, Sabate M, Angiolillo D, Alfonso F, Hernandez-Antolin R, Banuelos C, et al. LDL-cholesterol predicts negative coronary artery remodelling in diabetic patients: an intravascular ultrasound study. Eur Heart J. 2005;26(21):2307–12.CrossRefPubMed
5.
go back to reference Di Carli MF, Janisse J, Ager J, Grunberger G. Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. J Am Coll Cardiol. 2003;41(8):1387–93.CrossRefPubMed Di Carli MF, Janisse J, Ager J, Grunberger G. Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. J Am Coll Cardiol. 2003;41(8):1387–93.CrossRefPubMed
6.
go back to reference Hong YJ, Jeong MH, Choi YH, Ko JS, Lee MG, Kang WY, et al. Plaque characteristics in culprit lesions and inflammatory status in diabetic acute coronary syndrome patients. J Am Coll Cardiol Img. 2009;2(3):339–49.CrossRef Hong YJ, Jeong MH, Choi YH, Ko JS, Lee MG, Kang WY, et al. Plaque characteristics in culprit lesions and inflammatory status in diabetic acute coronary syndrome patients. J Am Coll Cardiol Img. 2009;2(3):339–49.CrossRef
7.
go back to reference Kato K, Yonetsu T, Kim SJ, Xing L, Lee H, McNulty I, et al. Comparison of nonculprit coronary plaque characteristics between patients with and without diabetes: a 3-vessel optical coherence tomography study. J Am Coll Cardiol Intv. 2012;5(11):1150–8.CrossRef Kato K, Yonetsu T, Kim SJ, Xing L, Lee H, McNulty I, et al. Comparison of nonculprit coronary plaque characteristics between patients with and without diabetes: a 3-vessel optical coherence tomography study. J Am Coll Cardiol Intv. 2012;5(11):1150–8.CrossRef
8.
go back to reference Sianos G, Morel M, Kappetein AP, Morice MC, Colombo A, et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention. 2005;1(2):219–27.PubMed Sianos G, Morel M, Kappetein AP, Morice MC, Colombo A, et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention. 2005;1(2):219–27.PubMed
9.
go back to reference Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Eur Heart J. 2012;33(20):2551–67.CrossRefPubMed Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Eur Heart J. 2012;33(20):2551–67.CrossRefPubMed
10.
go back to reference Tonino PA, Fearon WF, De Bruyne B, Oldroyd KG, Leesar MA, Ver Lee PN, et al. Angiographic versus functional severity of coronary artery stenoses in the FAME study fractional flow reserve versus angiography in multivessel evaluation. J Am Coll Cardiol. 2010;55(25):2816–21.CrossRefPubMed Tonino PA, Fearon WF, De Bruyne B, Oldroyd KG, Leesar MA, Ver Lee PN, et al. Angiographic versus functional severity of coronary artery stenoses in the FAME study fractional flow reserve versus angiography in multivessel evaluation. J Am Coll Cardiol. 2010;55(25):2816–21.CrossRefPubMed
11.
go back to reference De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367(11):991–1001.CrossRefPubMed De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367(11):991–1001.CrossRefPubMed
12.
go back to reference Rieber J, Jung P, Koenig A, Schiele T, Shapiro M, Hoffmann U, et al. Five-year follow-up in patients after therapy stratification based on intracoronary pressure measurement. Am Heart J. 2007;153(3):403–9.CrossRefPubMed Rieber J, Jung P, Koenig A, Schiele T, Shapiro M, Hoffmann U, et al. Five-year follow-up in patients after therapy stratification based on intracoronary pressure measurement. Am Heart J. 2007;153(3):403–9.CrossRefPubMed
13.
go back to reference Li J, Elrashidi MY, Flammer AJ, Lennon RJ, Bell MR, Holmes DR, et al. Long-term outcomes of fractional flow reserve-guided vs. angiography-guided percutaneous coronary intervention in contemporary practice. Eur Heart J. 2013;34(18):1375–83.CrossRefPubMedPubMedCentral Li J, Elrashidi MY, Flammer AJ, Lennon RJ, Bell MR, Holmes DR, et al. Long-term outcomes of fractional flow reserve-guided vs. angiography-guided percutaneous coronary intervention in contemporary practice. Eur Heart J. 2013;34(18):1375–83.CrossRefPubMedPubMedCentral
14.
go back to reference Depta JP, Patel JS, Novak E, Gage BF, Masrani SK, Raymer D, et al. Risk model for estimating the 1-year risk of deferred lesion intervention following deferred revascularization after fractional flow reserve assessment. Eur Heart J. 2015;36(8):509–15.CrossRefPubMed Depta JP, Patel JS, Novak E, Gage BF, Masrani SK, Raymer D, et al. Risk model for estimating the 1-year risk of deferred lesion intervention following deferred revascularization after fractional flow reserve assessment. Eur Heart J. 2015;36(8):509–15.CrossRefPubMed
15.
go back to reference Domínguez-Franco AJ, Jiménez-Navarro MF, Muñoz-García AJ, Alonso-Briales JH, Hernández-García JM, de Teresa Galvána E. Long-term prognosis in diabetic patients in whom revascularization is deferred following fractional flow reserve assessment. Rev Esp Cardiol. 2008;61(4):352–9.CrossRefPubMed Domínguez-Franco AJ, Jiménez-Navarro MF, Muñoz-García AJ, Alonso-Briales JH, Hernández-García JM, de Teresa Galvána E. Long-term prognosis in diabetic patients in whom revascularization is deferred following fractional flow reserve assessment. Rev Esp Cardiol. 2008;61(4):352–9.CrossRefPubMed
16.
go back to reference Nahser PJ Jr, Brown RE, Oskarsson H, Winniford MD, Rossen JD. Maximal coronary flow reserve and metabolic coronary vasodilation in patients with diabetes mellitus. Circulation. 1995;91(3):635–40.CrossRefPubMed Nahser PJ Jr, Brown RE, Oskarsson H, Winniford MD, Rossen JD. Maximal coronary flow reserve and metabolic coronary vasodilation in patients with diabetes mellitus. Circulation. 1995;91(3):635–40.CrossRefPubMed
17.
go back to reference Murthy VL, Naya M, Foster CR, Gaber M, Hainer J, Klein J, et al. Association between coronary vascular dysfunction and cardiac mortality in patients with and without diabetes mellitus. Circulation. 2012;126(15):1858–68.CrossRefPubMedPubMedCentral Murthy VL, Naya M, Foster CR, Gaber M, Hainer J, Klein J, et al. Association between coronary vascular dysfunction and cardiac mortality in patients with and without diabetes mellitus. Circulation. 2012;126(15):1858–68.CrossRefPubMedPubMedCentral
18.
go back to reference Kini AS, Kim MC, Moreno PR, Krishnan P, Ivan OC, Sharma SK. Comparison of coronary flow reserve and fractional flow reserve in patients with versus without diabetes mellitus and having elective percutaneous coronary intervention and abciximab therapy (from the PREDICT Trial). Am J Cardiol. 2008;101(6):796–800.CrossRefPubMed Kini AS, Kim MC, Moreno PR, Krishnan P, Ivan OC, Sharma SK. Comparison of coronary flow reserve and fractional flow reserve in patients with versus without diabetes mellitus and having elective percutaneous coronary intervention and abciximab therapy (from the PREDICT Trial). Am J Cardiol. 2008;101(6):796–800.CrossRefPubMed
19.
go back to reference Meuwissen M, Chamuleau SAJ, Siebes M, Schotborgh CE, Koch KT, de Winter RJ, et al. Role of variability in microvascular resistance on fractional flow reserve and coronary blood flow velocity reserve in intermediate coronary lesions. Circulation. 2001;103:184–7.CrossRefPubMed Meuwissen M, Chamuleau SAJ, Siebes M, Schotborgh CE, Koch KT, de Winter RJ, et al. Role of variability in microvascular resistance on fractional flow reserve and coronary blood flow velocity reserve in intermediate coronary lesions. Circulation. 2001;103:184–7.CrossRefPubMed
20.
go back to reference van de Hoef TP, van Lavieren MA, Damman P, Delewi R, Piek MA, Chamuleau SA, et al. Physiological basis and long-term clinical outcome of discordance between fractional flow reserve and coronary flow velocity reserve in coronary stenoses of intermediate severity. Circ Cardiovasc Interv. 2014;7(3):301–11.CrossRefPubMed van de Hoef TP, van Lavieren MA, Damman P, Delewi R, Piek MA, Chamuleau SA, et al. Physiological basis and long-term clinical outcome of discordance between fractional flow reserve and coronary flow velocity reserve in coronary stenoses of intermediate severity. Circ Cardiovasc Interv. 2014;7(3):301–11.CrossRefPubMed
21.
go back to reference Lee JM, Jung J-H, Hwang D, Park J, Fan Y, Na S-H, et al. Coronary flow reserve and microcirculatory resistance in patients with intermediate coronary stenosis. J Am Coll Cardiol. 2016;67(10):1158–69.CrossRefPubMed Lee JM, Jung J-H, Hwang D, Park J, Fan Y, Na S-H, et al. Coronary flow reserve and microcirculatory resistance in patients with intermediate coronary stenosis. J Am Coll Cardiol. 2016;67(10):1158–69.CrossRefPubMed
22.
go back to reference Liu Z, Matsuzawa Y, Herrmann J, Li J, Lennon RJ, Crusan DJ, et al. Relation between fractional flow reserve value of coronary lesions with deferred revascularization and cardiovascular outcomes in non-diabetic and diabetic patients. Int J Cardiol. 2016;219:56–62.CrossRefPubMed Liu Z, Matsuzawa Y, Herrmann J, Li J, Lennon RJ, Crusan DJ, et al. Relation between fractional flow reserve value of coronary lesions with deferred revascularization and cardiovascular outcomes in non-diabetic and diabetic patients. Int J Cardiol. 2016;219:56–62.CrossRefPubMed
23.
go back to reference Reith S, Battermann S, Hellmich M, Marx N, Burgmaier M. Impact of type 2 diabetes mellitus and glucose control on fractional flow reserve measurements in intermediate grade coronary lesions. Clin Res Cardiol. 2014;103(3):191–201.CrossRefPubMed Reith S, Battermann S, Hellmich M, Marx N, Burgmaier M. Impact of type 2 diabetes mellitus and glucose control on fractional flow reserve measurements in intermediate grade coronary lesions. Clin Res Cardiol. 2014;103(3):191–201.CrossRefPubMed
24.
go back to reference Bundhun PK, Li N, Chen MH. Adverse cardiovascular outcomes between insulin-treated and non-insulin treated diabetic patients after percutaneous coronary intervention: a systematic review and meta-analysis. Cardiovasc Diabetol. 2015;14:135.CrossRefPubMedPubMedCentral Bundhun PK, Li N, Chen MH. Adverse cardiovascular outcomes between insulin-treated and non-insulin treated diabetic patients after percutaneous coronary intervention: a systematic review and meta-analysis. Cardiovasc Diabetol. 2015;14:135.CrossRefPubMedPubMedCentral
25.
go back to reference Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364(3):226–35.CrossRefPubMed Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364(3):226–35.CrossRefPubMed
26.
go back to reference Marso SP, Mercado N, Maehara A, Weisz G, Mintz GS, McPherson J, et al. Plaque composition and clinical outcomes in acute coronary syndrome patients with metabolic syndrome or diabetes. J Am Coll Cardiol Img. 2012;5(3 Suppl):S42–52.CrossRef Marso SP, Mercado N, Maehara A, Weisz G, Mintz GS, McPherson J, et al. Plaque composition and clinical outcomes in acute coronary syndrome patients with metabolic syndrome or diabetes. J Am Coll Cardiol Img. 2012;5(3 Suppl):S42–52.CrossRef
27.
go back to reference Zhang M, Sara JD, Wang FL, Liu LP, Su LX, Zhe J, et al. Increased plasma BMP-2 levels are associated with atherosclerosis burden and coronary calcification in type 2 diabetic patients. Cardiovasc Diabetol. 2015;14:64.CrossRefPubMedPubMedCentral Zhang M, Sara JD, Wang FL, Liu LP, Su LX, Zhe J, et al. Increased plasma BMP-2 levels are associated with atherosclerosis burden and coronary calcification in type 2 diabetic patients. Cardiovasc Diabetol. 2015;14:64.CrossRefPubMedPubMedCentral
28.
go back to reference Kedhi E, Kennedy MW, Mehara A, Lansky AJ, McAndrew TC, Marso SP, et al. Impact of TCFA on unanticipated ischemic events in medically treated diabetes mellitus: Insights from the PROSPECT study. J Am Coll Cardiol Img. 2016. doi: 10.1016/j.jcmg.2015.12.023. Kedhi E, Kennedy MW, Mehara A, Lansky AJ, McAndrew TC, Marso SP, et al. Impact of TCFA on unanticipated ischemic events in medically treated diabetes mellitus: Insights from the PROSPECT study. J Am Coll Cardiol Img. 2016. doi: 10.1016/j.jcmg.2015.12.023.
29.
go back to reference Lazar HL, Chipkin SR, Fitzgerald CA, Bao Y, Cabral H, Apstein CS. Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. Circulation. 2004;109(12):1497–502.CrossRefPubMed Lazar HL, Chipkin SR, Fitzgerald CA, Bao Y, Cabral H, Apstein CS. Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. Circulation. 2004;109(12):1497–502.CrossRefPubMed
30.
go back to reference Stegman B, Puri R, Cho L, Shao M, Ballantyne CM, Barter PJ, et al. High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN. Diabetes Care. 2014;37(11):3114–20.CrossRefPubMed Stegman B, Puri R, Cho L, Shao M, Ballantyne CM, Barter PJ, et al. High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN. Diabetes Care. 2014;37(11):3114–20.CrossRefPubMed
31.
go back to reference Kataoka Y, Shao M, Wolski K, Uno K, Puri R, Tuzcu EM, et al. Multiple risk factor intervention and progression of coronary atherosclerosis in patients with type 2 diabetes mellitus. Eur J Prev Cardiol. 2013;20(2):209–17.CrossRefPubMed Kataoka Y, Shao M, Wolski K, Uno K, Puri R, Tuzcu EM, et al. Multiple risk factor intervention and progression of coronary atherosclerosis in patients with type 2 diabetes mellitus. Eur J Prev Cardiol. 2013;20(2):209–17.CrossRefPubMed
32.
go back to reference Kataoka Y, Yasuda S, Miyamoto Y, Sase K, Kosuge M, Kimura K, et al. Clinical predictors of atheroma progression despite optimal glycemic control in early-stage diabetic patients with coronary artery disease: insight from the DIANA study. J Atheroscler Thromb. 2014;21:509–18.CrossRefPubMed Kataoka Y, Yasuda S, Miyamoto Y, Sase K, Kosuge M, Kimura K, et al. Clinical predictors of atheroma progression despite optimal glycemic control in early-stage diabetic patients with coronary artery disease: insight from the DIANA study. J Atheroscler Thromb. 2014;21:509–18.CrossRefPubMed
33.
go back to reference Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the asteroid trial. JAMA. 2006;295(13):1556–65.CrossRefPubMed Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the asteroid trial. JAMA. 2006;295(13):1556–65.CrossRefPubMed
Metadata
Title
Clinical outcomes of deferred revascularisation using fractional flow reserve in patients with and without diabetes mellitus
Authors
Mark W. Kennedy
Eliza Kaplan
Rik S. Hermanides
Enrico Fabris
Veemal Hemradj
Petra C. Koopmans
Jan-Hank E. Dambrink
A. T. Marcel Gosselink
Arnoud W. J. van‘t Hof
Jan Paul Ottervanger
Vincent Roolvink
Wouter S. Remkes
Aize van der Sluis
Harry Suryapranata
Elvin Kedhi
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2016
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-016-0417-2

Other articles of this Issue 1/2016

Cardiovascular Diabetology 1/2016 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.